raloxifene hydrochloride has been researched along with Bone Loss, Osteoclastic in 86 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (13.95) | 18.2507 |
| 2000's | 52 (60.47) | 29.6817 |
| 2010's | 21 (24.42) | 24.3611 |
| 2020's | 1 (1.16) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, L; Qian, HJ; Tan, MS; Yang, N; Zhang, LK; Zhang, YY | 1 |
| Allen, MR; Alvarez, MB; Bidwell, JP; Burr, DB; Childress, P; Condon, KW; Davis, H; He, Y; Hernandez-Buquer, S; Plotkin, LI; Robling, AG; Shao, Y; Stayrook, KR; Warden, SJ; Wek, RC; Yang, FC | 1 |
| Bi, DD; Guo, YF; Han, MH; Hao, T; Liu, H; Qi, XY; Wang, XG; Wang, XT; Zhang, BX | 1 |
| Eastell, R; Finigan, J; Naylor, K; Paggiosi, MA; Peel, NF | 1 |
| Ehlert, KM; Hernandez, CJ; Lin, I; Matheny, JB; Slyfield, CR; Tkachenko, EV; Tomlinson, RE; Wilson, DL | 1 |
| Baas, J; Barckman, J; Bechtold, JE; Hermansen, LL; Søballe, K; Sørensen, M | 1 |
| Hirai, K; Inoue, T; Kanehara, H; Nagatoya, K; Nishimoto, K; Okada, S; Shibahara, N; Takahashi, T; Ueda, H; Ueno, N; Yasuda, H | 1 |
| Compston, J | 1 |
| Kalam, A; Talegaonkar, S; Vohora, D | 1 |
| Kobayashi, T; Matsumoto, M; Miyamoto, K; Miyamoto, T; Morita, M; Nakamura, M; Oike, T; Sato, Y; Tando, T; Watanabe, R | 1 |
| Calignano, A; Corrado, B; Lama, A; Mattace Raso, G; Meli, R; Paciello, O; Pagano, TB; Pirozzi, C; Russo, S; Santoro, A | 1 |
| Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L | 1 |
| Pepersack, T | 1 |
| Stepan, JJ; Zikan, V | 1 |
| Boekhoff, J; Herrmann, TR; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, H; Tezval, M; Wuttke, W | 1 |
| Cegieła, U; Folwarczna, J; Kaczmarczyk-Sedlak, I; Nowińska, B; Pytlik, M; Sliwiński, L; Trzeciak, H; Trzeciak, HI | 1 |
| Oshima, H; Tanaka, I | 1 |
| Inaba, M; Shidara, K | 1 |
| Ohnaka, K; Takayanagi, R | 1 |
| Gorai, I; Hattori, S; Iwaoki, Y; Tanaka, Y | 1 |
| Harris, ST; Mitchner, NA | 1 |
| Iba, K; Takada, J; Yamashita, T; Yoshizaki, T | 2 |
| Shimada, H; Takami, M | 1 |
| Canpolat, S; Kumru, S; Seyran, AD; Tug, N; Yilmaz, B | 1 |
| Gong, YX; Huang, L; Liu, JM; Lu, SY; Pang, XF; Wang, ZG; Xu, Y; Yan, MZ; Zhao, YJ | 1 |
| Enokida, M; Hagino, H; Hayashi, I; Okano, T; Teshima, R | 1 |
| Bhat, KM; Nampurath, GK; Potu, BK; Rao, MS | 1 |
| Bauer, DC; Schousboe, JT | 1 |
| Dwivedi, C; Khan, S; Parmar, V; Shirwaikar, A; Srinivasan, KK | 1 |
| Eriguchi, M; Haruyama, N; Kitazono, T; Nakano, T; Tanaka, S; Taniguchi, M; Tsuruya, K; Yamada, S; Yoshida, H | 1 |
| Celi, M; D'Erasmo, E; Letizia, C; Mazzuoli, GF; Minisola, S; Ragno, A | 1 |
| Matsumoto, T | 1 |
| Bryant, HU; Cole, HW; Hoover, J; Jee, WS; Ma, YL; Sato, M; Schmidt, A; Yao, W; Zeng, Q | 1 |
| Calcagnile, F; Carlo Isaia, G; Cosentino, L; D'Amelio, P; Muratore, M; Quarta, E; Tamone, C; Tinelli, F | 1 |
| Anderson, DW; Bhagwat, SS; Brady, H; Gayo-Fung, LM; Leisten, J; Lipps, SG; McKie, JA; O'Leary, E; Patnaik, N; Stein, B; Sutherland, MK | 1 |
| Burde, MA; Cohen-Solal, ME; de Vernejoul, MC; Maudelonde, T; Rey, JM; Saintier, D | 1 |
| Bonn, D | 1 |
| Itabashi, A | 1 |
| Ferrer-Barriendos, J; Gaines, K; Geusens, P; Melton, ME; Ribot, C; Sambrook, PN; Solimano, JA; Verbruggen, N | 1 |
| Alenfeld, F; Boivin, G; Feyen, JH; Lakatos, P; Stepan, JJ | 1 |
| Ammann, P; Baron, R; Bourrin, S; Brunner, F; Clément-Lacroix, P; Gaillard, M; Meyer, JM; Rizzoli, R | 1 |
| Ohta, H | 3 |
| Hamaya, E; Kobayashi, H | 1 |
| Falbo, A; Lombardi, G; Manguso, F; Mastrantonio, P; Nunziata, V; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F | 1 |
| Hosking, DJ; Pande, I | 1 |
| Brixen, K; Mosekilde, L; Vestergaard, P | 1 |
| Bashir, A; Cheung, J; Fogelman, I; Grigoriadis, AE; Hampson, G; Mak, YT; McGowan, NW; Sankaralingam, S | 1 |
| Ellerbeck, EF; Jachna, CM; Rigler, SK; Shireman, TI; Whittle, J | 1 |
| Altunyurt, S; Cakmak, A; Caliskan, S; Dogan, E; Guclu, S; Posaci, C | 1 |
| Brown, SA; Rosen, CJ | 1 |
| Armamento-Villareal, R; Brodt, MD; Caruso, PL; Civelli, M; Civitelli, R; Galbiati, E; Halstead, LR; Mueller, C; Napoli, N; Nawaz, A; Sheikh, S; Silva, MJ | 1 |
| Matsuno, A; Okazaki, R; Okinaga, H | 1 |
| Takada, J | 1 |
| Narayana Murthy, PS; Sengupta, S; Sharma, S; Singh, MM | 1 |
| Fassbender, WJ; Kurth, A; Stumpf, UC | 1 |
| Asano, S; Kanematsu, M; Kikkawa, H; Kinoshita, M; Mitamura, M; Xiang, A | 1 |
| Odvina, CV | 1 |
| Jordan, VC | 1 |
| Cremers, S; Garnero, P | 1 |
| Järvinen, TL; Kannus, P; Sievänen, H | 1 |
| Härkönen, PL; Hentunen, TA; Kangas, L; Michael, H; Väänänen, HK | 1 |
| Barbuto, N; Cosman, F; Lindsay, R; Nieves, JW; Zion, M | 1 |
| Mashiba, T | 1 |
| Fournier, B; Hall, TJ; Nyugen, H; Schaueblin, M | 1 |
| Bryant, HU; Evans, G; Magee, D; Sato, M; Turner, RT | 1 |
| Bekele, A; Bendele, R; Bensch, WR; Black, LJ; Cullinan, GJ; Kauffman, RF; Magee, DE; Rowley, ER; Sato, M; Williams, DC | 1 |
| Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE | 1 |
| Raisz, LG | 1 |
| Bryant, HU; Cho, S; Dodge, JA; Frolik, CA; Glasebrook, AL; Lugar, CW; Martin, MJ; Osborne, JJ; Phillips, DL; Sato, M; Short, LL; Spangle, LA; Yang, NN | 1 |
| Draper, MW; Heaney, RP | 1 |
| Bryant, HU; Dere, WH | 1 |
| Zaidi, M | 1 |
| Christiansen, C | 1 |
| Chapman, B | 1 |
| Kleerekoper, M | 1 |
| Ito, M; Miyaura, C; Nozawa, S; Ohta, H; Onoe, Y; Suda, T | 1 |
| Bénichou, O; Cohen-Solal, M; de Vernejoul, MC | 1 |
| Bélanger, A; Labrie, C; Labrie, F; Martel, C; Picard, S; Richard, V | 1 |
| Delmas, PD; Eastell, R; Garnero, P; Seibel, MJ; Stepan, J | 1 |
| Atkinson, EJ; Doran, PM; Khosla, S; Riggs, BL | 1 |
| Harper, K; Lips, P; Lu, Y; Oleksik, A; Ott, SM | 1 |
25 review(s) available for raloxifene hydrochloride and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Emerging therapeutic concepts for muscle and bone preservation/building.
Topics: Anabolic Agents; Animals; Bone Density; Bone Remodeling; Bone Resorption; Denosumab; Diphosphonates; Fractures, Bone; Humans; Muscle, Skeletal; Osteoporosis; Raloxifene Hydrochloride | 2015 |
[Treatment of osteoporosis in octogenarians].
Topics: Aged, 80 and over; Attitude to Health; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Fractures, Bone; Frail Elderly; Humans; Osteoporosis; Perception; Raloxifene Hydrochloride | 2008 |
[Drug selection guide for osteoporosis determined by the clinical staging, pathophysiology and age].
Topics: Age Factors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Calcium; Diphosphonates; Drug Therapy, Combination; Female; Hip Fractures; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk; Vitamin D | 2009 |
[Bone metabolic marker for osteoporosis].
Topics: Acid Phosphatase; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Diphosphonates; Female; Fractures, Bone; Humans; Isoenzymes; Osteoporosis; Peptides; Raloxifene Hydrochloride; Risk Assessment; Tartrate-Resistant Acid Phosphatase | 2009 |
[Biochemical markers of bone turnover. New aspect. Effects of androgen and estrogen on biochemical markers of bone turnover].
Topics: Androgens; Biomarkers; Bone and Bones; Bone Remodeling; Bone Resorption; Estrogen Replacement Therapy; Estrogens; Female; Humans; Male; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2009 |
Current and emerging therapies for osteoporosis.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Drug Therapy, Combination; Estrogens; Humans; Osteoporosis; Raloxifene Hydrochloride; Teriparatide; Treatment Outcome | 2009 |
[Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
Topics: Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Femur; Humans; Osteogenesis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Teriparatide | 2010 |
[Effects of SERMs on bone health. SERM and metabolic markers of bone].
Topics: Acid Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Isoenzymes; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tartrate-Resistant Acid Phosphatase | 2010 |
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Monitoring, Physiologic; Osteoporotic Fractures; Raloxifene Hydrochloride; Wound Healing; Zoledronic Acid | 2012 |
[Osteoporosis].
Topics: Animals; Bone Resorption; Calcitriol; Clinical Trials as Topic; Diphosphonates; Humans; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Vitamin D | 2002 |
[Raloxifene hydrochloride].
Topics: Arteriosclerosis; Bone Density; Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures | 2004 |
Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Remodeling; Bone Resorption; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2003 |
[Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Topics: Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Female; Femoral Neck Fractures; Humans; Osteocalcin; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures | 2004 |
[Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Controlled Clinical Trials as Topic; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stroke; Transcription Factors | 2005 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide | 2005 |
[Treatment of osteoporosis with antiresorptive drugs].
Topics: Bone Density; Bone Resorption; Calcitonin; Calcium; Cholecalciferol; Diphosphonates; Estradiol; Estrogens, Conjugated (USP); Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Progesterone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D | 2005 |
[SERMs: an update for clinicians].
Topics: Animals; Bone and Bones; Bone Resorption; Drug Design; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2005 |
A rational approach to evidence gaps in the management of osteoporosis.
Topics: Age Factors; Aged; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Case Management; Cohort Studies; Diphosphonates; Drug Therapy, Combination; Estrogens; Evidence-Based Medicine; Female; Follow-Up Studies; Fractures, Spontaneous; Health Surveys; Hip Fractures; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Risk Assessment; Spinal Fractures; Time Factors | 2005 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
[Effect of raloxifene as a SERM on bone metabolism].
Topics: Bone and Bones; Bone Density; Bone Resorption; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2006 |
Osteoporosis: how should it be treated?
Topics: Bone Density; Bone Resorption; Calcitonin; Diphosphonates; Drug Therapy, Combination; Estrogens; Humans; Osteoporosis; Parathyroid Hormone; Peptide Fragments; Raloxifene Hydrochloride | 2006 |
Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Remodeling; Bone Resorption; Calcitonin; Cathepsin K; Cathepsins; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Drug Design; Female; Humans; Organometallic Compounds; Osteitis Deformans; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; RANK Ligand; Thiophenes | 2006 |
[Assessment of bone quality. Bone quality and osteoporosis treatment].
Topics: Aging; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Calcification, Physiologic; Diphosphonates; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2008 |
Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
Topics: Bone Resorption; Cholesterol; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Uterus | 1998 |
The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.
Topics: Biomarkers; Bone Density; Bone Regeneration; Bone Remodeling; Bone Resorption; Diphosphonates; Estrogens; Female; Fractures, Spontaneous; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Periodicity; Prognosis; Raloxifene Hydrochloride; Risk Assessment; Terminology as Topic | 2000 |
12 trial(s) available for raloxifene hydrochloride and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Raloxifene Prevents Early Periprosthetic Bone Loss for Postmenopausal Women after Uncemented Total Hip Arthroplasty: A Randomized Placebo-Controlled Clinical Trial.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Bone Resorption; Disability Evaluation; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Postoperative Complications; Prospective Studies; Quality of Life; Raloxifene Hydrochloride | 2020 |
Adherence to raloxifene therapy: assessment methods and relationship with efficacy.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Drug Administration Schedule; Drug Monitoring; Drug Packaging; Electrical Equipment and Supplies; England; Female; Humans; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Tablets | 2013 |
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Chelating Agents; Collagen Type I; Edetic Acid; Etidronic Acid; Female; Humans; Hypocalcemia; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Raloxifene Hydrochloride; Risedronic Acid | 2009 |
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Drug Therapy, Combination; Female; Humans; Hydroxycholecalciferols; Japan; Medication Adherence; Middle Aged; Osteogenesis; Osteoporosis, Postmenopausal; Patient Dropouts; Raloxifene Hydrochloride; Statistics as Topic; Surveys and Questionnaires; Time Factors | 2010 |
Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Cholecalciferol; Clodronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2003 |
Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; Double-Blind Method; Female; Hip; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Time Factors; Treatment Outcome | 2004 |
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Drug Combinations; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Genotype; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Receptors, Calcitriol; Selective Estrogen Receptor Modulators; Treatment Outcome | 2005 |
Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Topics: Aged; Bone Density; Bone Resorption; Carrier Proteins; Collagen; Collagen Type I; Estrogens; Female; Gene Expression Regulation; Glycoproteins; Hormone Replacement Therapy; Humans; Leukocytes, Mononuclear; Longitudinal Studies; Membrane Glycoproteins; Middle Aged; Osteoporosis; Osteoprotegerin; Peptides; Postmenopause; Raloxifene Hydrochloride; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; RNA, Messenger; Selective Estrogen Receptor Modulators | 2005 |
Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Treatment Outcome | 2008 |
Raloxifene and estrogen: comparative bone-remodeling kinetics.
Topics: Bone Remodeling; Bone Resorption; Calcium; Creatinine; Estrogen Antagonists; Estrogens; Female; Humans; Hydroxyproline; Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride | 1997 |
Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men.
Topics: Aged; Biomarkers; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Estradiol; Follicle Stimulating Hormone; Gonadal Steroid Hormones; Humans; Lipids; Luteinizing Hormone; Male; Middle Aged; Osteoporosis; Parathyroid Hormone; Peptides; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2001 |
Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women.
Topics: Aged; Biopsy; Bone Density; Bone Resorption; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures | 2002 |
49 other study(ies) available for raloxifene hydrochloride and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.
Topics: Animals; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Imidazoles; Mice; Mice, Knockout; Nuclear Matrix-Associated Proteins; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Transcription Factors; Zoledronic Acid | 2017 |
Combined administration on You-Gui Yin and low-dose Raloxifene partially attenuates the bone loss in ovariectomized mice through the proliferation and osteogenic differentiation of bone marrow stromal cells.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Proliferation; Disease Models, Animal; Drug Synergism; Drugs, Chinese Herbal; Female; Mesenchymal Stem Cells; Mice, Inbred C57BL; Osteogenesis; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Tibia | 2019 |
Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study.
Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Etidronic Acid; Female; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2013 |
Incorporation of raloxifene-impregnated allograft around orthopedic titanium implants impairs early fixation but improves new bone formation.
Topics: Allografts; Animals; Bone Density Conservation Agents; Bone Resorption; Bone Transplantation; Dogs; Osseointegration; Osteogenesis; Prostheses and Implants; Raloxifene Hydrochloride; Tibia; Titanium | 2015 |
Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Female; Humans; Isoenzymes; Kidney Failure, Chronic; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Renal Dialysis; Tartrate-Resistant Acid Phosphatase | 2015 |
Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice.
Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers; Bone Remodeling; Bone Resorption; Cyclohexenes; Female; Femur; Glycoproteins; Intercellular Signaling Peptides and Proteins; Letrozole; Lumbar Vertebrae; Menopause; Mice; Nitriles; Raloxifene Hydrochloride; Triazoles; Vinyl Compounds | 2017 |
Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Indoles; Male; Mice; Mice, Inbred C57BL; Orchiectomy; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Testosterone; Vitamin D | 2017 |
Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats.
Topics: Adiponectin; Animals; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Female; High-Energy Shock Waves; Osteogenesis; Osteoporosis; Ovariectomy; PPAR gamma; Raloxifene Hydrochloride; Rats; Transcription, Genetic | 2017 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Confounding Factors, Epidemiologic; Dietary Supplements; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Logistic Models; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2009 |
Effect of testosterone, raloxifene and estrogen replacement on the microstructure and biomechanics of metaphyseal osteoporotic bones in orchiectomized male rats.
Topics: Administration, Oral; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Resorption; Disease Models, Animal; Estrogens; Hormone Replacement Therapy; Male; Orchiectomy; Osteoporosis; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Testosterone | 2009 |
A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
Topics: Animals; Body Weight; Bone and Bones; Bone Density; Bone Marrow Cells; Bone Resorption; Calcification, Physiologic; Calcium; Cell Count; Cells, Cultured; Disease Models, Animal; Drug Combinations; Estradiol; Estriol; Female; Gene Expression; Genistein; Humans; Mice; Mice, Inbred BALB C; Organ Size; Osteoblasts; Osteoclasts; Osteoporosis, Postmenopausal; Ovariectomy; Phytoestrogens; Raloxifene Hydrochloride; Rats; Rats, Wistar; RNA, Messenger; Selective Estrogen Receptor Modulators; Thymus Gland; Uterus | 2009 |
Effects of raloxifene and estradiol on bone turnover parameters in intact and ovariectomized rats.
Topics: Alkaline Phosphatase; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Estradiol; Female; Osteocalcin; Ovariectomy; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley | 2010 |
Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cell Count; Elastic Modulus; Female; Femur; Gene Expression Regulation; Lumbar Vertebrae; Mechanical Phenomena; Mice; Mice, Knockout; Osteoclasts; Osteoprotegerin; Raloxifene Hydrochloride; Random Allocation; RANK Ligand; RNA, Messenger | 2010 |
Effect of raloxifene on arthritis and bone mineral density in rats with collagen-induced arthritis.
Topics: Animals; Arthritis; Arthritis, Experimental; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Female; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley | 2011 |
Effect of Cissus quadrangularis Linn on the development of osteopenia induced by ovariectomy in rats.
Topics: Acid Phosphatase; Alkaline Phosphatase; Alkanes; Animals; Biomarkers; Bone Diseases, Metabolic; Bone Resorption; Calcium; Cissus; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Femur; Humans; Hydroxyproline; Isoenzymes; Osteoporosis, Postmenopausal; Ovariectomy; Phytotherapy; Plant Extracts; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase | 2011 |
Correlation between a bone resorption marker and structural geometry of the proximal femur in osteoporotic women treated with raloxifene.
Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Female; Femur; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride | 2012 |
Methanol extract of dried exudate of Commiphora mukul prevents bone resorption in ovariectomized rats.
Topics: Acid Phosphatase; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Cholesterol; Commiphora; Dose-Response Relationship, Drug; Female; Isoenzymes; Methanol; Ovariectomy; Plant Extracts; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase | 2012 |
The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Topics: Acid Phosphatase; Acute Kidney Injury; Adult; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Resorption; Cinacalcet; Collagen Type I; Cross-Sectional Studies; Female; Humans; Hydroxycholecalciferols; Isoenzymes; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Peptides; Peritoneal Dialysis; Raloxifene Hydrochloride; Regression Analysis; Tartrate-Resistant Acid Phosphatase | 2013 |
ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Number 39, October 2002. Selective estrogen receptor modulators.
Topics: Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Endometrium; Female; Genitalia, Female; Hot Flashes; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism | 2002 |
[Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis].
Topics: Analysis of Variance; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Case-Control Studies; Drug Therapy, Combination; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Sodium Fluoride | 2002 |
New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Resorption; Drug Administration Schedule; Ethinyl Estradiol; Female; Femur; Osteogenesis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Spine; Tensile Strength; Teriparatide; Tibia; Time Factors | 2003 |
Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
Topics: Administration, Oral; Animals; Body Weight; Bone Density; Bone Resorption; Cholesterol; Coumarins; Dose-Response Relationship, Drug; Female; Femur; Organ Size; Ovariectomy; Piperidines; Radiography; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Triglycerides; Uterus | 2003 |
17beta-estradiol downregulates beta3-integrin expression in differentiating and mature human osteoclasts.
Topics: Blotting, Western; Bone and Bones; Bone Resorption; Cell Differentiation; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Fluorescent Antibody Technique; Humans; Integrin beta3; Organ Culture Techniques; Osteoclasts; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2004 |
New ways with old bones. Osteoporosis researchers look for drugs to replace hormone replacement therapy.
Topics: Antioxidants; Bone Resorption; Carrier Proteins; Contraindications; Female; Hormone Replacement Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoflavones; Leptin; Membrane Glycoproteins; Osteoporosis; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Selective Estrogen Receptor Modulators; Teriparatide | 2004 |
A new selective estrogen receptor modulator HMR-3339 fully corrects bone alterations induced by ovariectomy in adult rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Resorption; Compressive Strength; Estradiol; Female; Osteocalcin; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators | 2004 |
Differing patterns of antiresorptive pharmacotherapy in nursing facility residents and community dwellers.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Bone Resorption; Calcitonin; Cross-Sectional Studies; Demography; Diphosphonates; Female; Hormone Replacement Therapy; Humans; Nursing Homes; Osteoporosis; Raloxifene Hydrochloride; Residence Characteristics | 2005 |
Raloxifene increases serum leptin levels in postmenopausal women: a prospective study.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Collagen; Collagen Type I; Female; Humans; Insulin-Like Growth Factor I; Leptin; Middle Aged; Osteocalcin; Peptides; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2005 |
A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
Topics: Absorptiometry, Photon; Amino Acids; Animals; Benzopyrans; Biomechanical Phenomena; Blood; Body Composition; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Cholesterol; Compressive Strength; Estrogen Receptor Modulators; Ethinyl Estradiol; Female; Femur; Femur Neck; Lumbar Vertebrae; Organ Size; Osteoclasts; Osteogenesis; Ovariectomy; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Tibia; Tomography, X-Ray Computed; Triglycerides; Uterus; Weight-Bearing | 2005 |
High risk of osteopenia and bone derangement in postsurgical patients with craniopharyngiomas, pituitary adenomas and other parasellar lesions.
Topics: Adolescent; Adult; Aged; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Child; Collagen; Collagen Type I; Craniopharyngioma; Diphosphonates; Estrogens; Female; Follicle Stimulating Hormone; Gonadotropins; Humans; Hydrocortisone; Hypopituitarism; Luteinizing Hormone; Male; Middle Aged; Peptides; Pituitary Neoplasms; Raloxifene Hydrochloride; Risk Factors; Testosterone; Thyroxine | 2005 |
Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.
Topics: Animals; Apoptosis; Benzopyrans; Bone Density; Bone Marrow Cells; Bone Resorption; Calcium; Cell Differentiation; Cells, Cultured; Female; Lumbar Vertebrae; Mice; Mice, Inbred BALB C; Organ Size; Osteoclasts; Ovariectomy; Phosphorus; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Stem Cells; Transforming Growth Factor beta; Transforming Growth Factor beta3; Uterus | 2006 |
[The successful development of bisphosphonates in the therapy of osteoporosis].
Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Estrogen Antagonists; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Primary Prevention; Raloxifene Hydrochloride; Risk Reduction Behavior | 2006 |
Analysis of change patterns of microcomputed tomography 3-dimensional bone parameters as a high-throughput tool to evaluate antiosteoporotic effects of agents at an early stage of ovariectomy-induced osteoporosis in mice.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Early Diagnosis; Estradiol; Female; Femur; Imaging, Three-Dimensional; Mice; Osteogenesis; Osteoporosis; Ovariectomy; Parathyroid Hormone; Peptide Fragments; Raloxifene Hydrochloride; Rolipram; Tomography, X-Ray Computed | 2006 |
A STAR is born.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2006 |
Bone quality: an empty term.
Topics: Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Fractures, Bone; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2007 |
Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Topics: Animals; Apoptosis; Bone Resorption; Cattle; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Dexamethasone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Lipopolysaccharide Receptors; Macrophage Colony-Stimulating Factor; Monocytes; Osteoclasts; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Tumor Necrosis Factor-alpha | 2007 |
The bone-specific estrogen centchroman inhibits osteoclastic bone resorption in vitro.
Topics: Animals; Animals, Newborn; Bone Resorption; Calcitonin; Cells, Cultured; Centchroman; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Humans; Kinetics; Molecular Structure; Osteoclasts; Piperidines; Raloxifene Hydrochloride; Rats; Structure-Activity Relationship | 1995 |
The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
Topics: Aging; Animals; Body Weight; Bone and Bones; Bone Development; Bone Resorption; Cell Count; Cholesterol; Female; Organ Size; Osteoclasts; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tibia; Uterus | 1994 |
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Body Weight; Bone Density; Bone Resorption; Calcium; Cholesterol; Dose-Response Relationship, Drug; Epithelial Cells; Epithelium; Estrogen Antagonists; Ethinyl Estradiol; Female; Hypertrophy; Ovariectomy; Phosphorus; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Triglycerides; Uterus | 1994 |
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Models, Animal; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Organ Size; Osteoporosis, Postmenopausal; Ovariectomy; Piperidines; Radioimmunoassay; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1996 |
Estrogen and bone: new pieces to the puzzle.
Topics: Animals; Bone Resorption; Estradiol; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation; Humans; Mice; Osteoblasts; Osteoclasts; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transforming Growth Factor beta | 1996 |
Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.
Topics: Adenocarcinoma; Animals; Bone Resorption; Breast Neoplasms; Cell Division; Cells, Cultured; Estradiol; Estrogen Antagonists; Female; Glucuronates; Humans; Interleukin-6; Organ Specificity; Osteoclasts; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tissue Distribution; Transforming Growth Factor beta; Tumor Cells, Cultured | 1997 |
Biological basis of anti-resorptive therapies for osteoporosis.
Topics: Aged; Alendronate; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Sex steroid analogs.
Topics: Animals; Bone Resorption; Breast Neoplasms; Estrogen Antagonists; Female; Gonadal Steroid Hormones; Hormones; Humans; Norpregnenes; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Tamoxifen | 1999 |
Biochemical bone markers.
Topics: Alendronate; Biomarkers; Bone Remodeling; Bone Resorption; Diphosphonates; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Lipids; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1999 |
Frequency of bone densitometry for osteoporosis?
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Time Factors | 1999 |
Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice.
Topics: Androgens; Animals; B-Lymphocytes; Bone Marrow; Bone Remodeling; Bone Resorption; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Hematopoiesis; Humans; Lymphocyte Count; Male; Mice; Orchiectomy; Organ Size; Osteoporosis; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Uterus | 2000 |
[Physiopathology of bone loss and pharmacologic approach of selective estrogen receptor modulators].
Topics: Animals; Bone Resorption; Cytokines; Estrogens; Female; Humans; Interleukin-6; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2000 |
Drugs for prevention and treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calcitonin; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Densitometry; Dose-Response Relationship, Drug; Estrogens; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Vitamin D | 2000 |
Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.
Topics: Administration, Oral; Amino Acids; Animals; Benzopyrans; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Cholesterol; Disease Models, Animal; Epithelial Cells; Estradiol; Estrogens; Female; Femur; Lumbar Vertebrae; Organ Size; Ovariectomy; Postmenopause; Propionates; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tibia; Time Factors; Triglycerides; Uterus | 2000 |